312 related articles for article (PubMed ID: 31661167)
1. Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth.
Carbonetti G; Converso C; Clement T; Wang C; Trotman LC; Ojima I; Kaczocha M
Prostate; 2020 Jan; 80(1):88-98. PubMed ID: 31661167
[TBL] [Abstract][Full Text] [Related]
2. Lack of combination effects of soy isoflavones and taxane chemotherapy of castration-resistant prostate cancer.
Eskra JN; Schlicht MJ; Bosland MC
Prostate; 2019 Feb; 79(2):223-233. PubMed ID: 30345530
[TBL] [Abstract][Full Text] [Related]
3. Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
Hillowe A; Gordon C; Wang L; Rizzo RC; Trotman LC; Ojima I; Bialkowska A; Kaczocha M
PLoS One; 2023; 18(10):e0292483. PubMed ID: 37796964
[TBL] [Abstract][Full Text] [Related]
4. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
[TBL] [Abstract][Full Text] [Related]
5. Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Watanabe H; Kawakami A; Sato R; Watanabe K; Matsushita Y; Miyake H
Anticancer Res; 2021 Aug; 41(8):3753-3758. PubMed ID: 34281834
[TBL] [Abstract][Full Text] [Related]
6. Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Ishii K; Matsuoka I; Kajiwara S; Sasaki T; Miki M; Kato M; Kanda H; Arima K; Shiraishi T; Sugimura Y
J Cancer Res Clin Oncol; 2018 Jan; 144(1):89-98. PubMed ID: 29098395
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System.
Qu Z; Ren Y; Shen H; Wang H; Shi L; Tong D
Drug Des Devel Ther; 2021; 15():3605-3616. PubMed ID: 34447241
[TBL] [Abstract][Full Text] [Related]
8. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer.
de Leeuw R; Berman-Booty LD; Schiewer MJ; Ciment SJ; Den RB; Dicker AP; Kelly WK; Trabulsi EJ; Lallas CD; Gomella LG; Knudsen KE
Clin Cancer Res; 2015 Feb; 21(4):795-807. PubMed ID: 25691773
[TBL] [Abstract][Full Text] [Related]
9. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Li X; Wu JB; Chung LW; Huang WC
Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
[TBL] [Abstract][Full Text] [Related]
10. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors.
Vrignaud P; Sémiond D; Lejeune P; Bouchard H; Calvet L; Combeau C; Riou JF; Commerçon A; Lavelle F; Bissery MC
Clin Cancer Res; 2013 Jun; 19(11):2973-83. PubMed ID: 23589177
[TBL] [Abstract][Full Text] [Related]
12. Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation.
de Morrée E; van Soest R; Aghai A; de Ridder C; de Bruijn P; Ghobadi Moghaddam-Helmantel I; Burger H; Mathijssen R; Wiemer E; de Wit R; van Weerden W
Prostate; 2016 Jul; 76(10):927-36. PubMed ID: 26997363
[TBL] [Abstract][Full Text] [Related]
13. Can taxanes provide benefit in patients with CNS tumors and in pediatric patients with tumors? An update on the preclinical development of cabazitaxel.
Sémiond D; Sidhu SS; Bissery MC; Vrignaud P
Cancer Chemother Pharmacol; 2013 Sep; 72(3):515-28. PubMed ID: 23820961
[TBL] [Abstract][Full Text] [Related]
14. Preclinical profile of cabazitaxel.
Vrignaud P; Semiond D; Benning V; Beys E; Bouchard H; Gupta S
Drug Des Devel Ther; 2014; 8():1851-67. PubMed ID: 25378905
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
16. Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells.
Eskra JN; Schlicht MJ; Bosland MC
Sci Rep; 2019 Mar; 9(1):4367. PubMed ID: 30867440
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation of a Cabazitaxel Prodrug Using Nanoparticle Delivery for the Treatment of Taxane-Resistant Malignancies.
Xie B; Wan J; Chen X; Han W; Wang H
Mol Cancer Ther; 2020 Mar; 19(3):822-834. PubMed ID: 31848296
[TBL] [Abstract][Full Text] [Related]
18. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
[TBL] [Abstract][Full Text] [Related]
19. Inhibitor SBFI26 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5.
Al-Jameel W; Gou X; Forootan SS; Al Fayi MS; Rudland PS; Forootan FS; Zhang J; Cornford PA; Hussain SA; Ke Y
Oncotarget; 2017 May; 8(19):31041-31056. PubMed ID: 28415688
[TBL] [Abstract][Full Text] [Related]
20. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Yu DC; Chen Y; Dilley J; Li Y; Embry M; Zhang H; Nguyen N; Amin P; Oh J; Henderson DR
Cancer Res; 2001 Jan; 61(2):517-25. PubMed ID: 11212244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
